Chimeric immunomodulatory compounds and methods of using the same-II
First Claim
Patent Images
1. A chimeric immunomodulatory compound (CIC) comprising a core structure with the formula [Nv]x—
- Sp, wherein Sp is a multivalent spacer moiety covalently bonded to X independently selected nucleic acid moieties (Nv), wherein the nucleic acid moieties are between 3 and 7 nucleotides, wherein X is at least 3, wherein said multivalent spacer moiety is selected from the group consisting of a polysaccharide, glycerol, substituted glycerol, tetraaminobenzene, heptaaminobetacyclodextrin, 1,3,5-trihydroxycyclohexane, pentaerythritol, 1,3-diamino-2-propanol, substituted derivatives of 1,3,-diamino-2-propanol, [propyloxymethyl]ethyl compounds, tetraaminopentaerythritol, 1,4,8,11-tetraazacyclotetradecane, 1,4,7,10-tetraazacyclododecane, polyethyleneimino, or a 2-(hydroxymethyl)ethyl moiety, and wherein said CIC further comprises at least one additional non-nucleic acid spacer moiety.
3 Assignments
0 Petitions
Accused Products
Abstract
The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.
-
Citations
34 Claims
-
1. A chimeric immunomodulatory compound (CIC) comprising a core structure with the formula [Nv]x—
- Sp, wherein Sp is a multivalent spacer moiety covalently bonded to X independently selected nucleic acid moieties (Nv), wherein the nucleic acid moieties are between 3 and 7 nucleotides, wherein X is at least 3, wherein said multivalent spacer moiety is selected from the group consisting of a polysaccharide, glycerol, substituted glycerol, tetraaminobenzene, heptaaminobetacyclodextrin, 1,3,5-trihydroxycyclohexane, pentaerythritol, 1,3-diamino-2-propanol, substituted derivatives of 1,3,-diamino-2-propanol, [propyloxymethyl]ethyl compounds, tetraaminopentaerythritol, 1,4,8,11-tetraazacyclotetradecane, 1,4,7,10-tetraazacyclododecane, polyethyleneimino, or a 2-(hydroxymethyl)ethyl moiety, and wherein said CIC further comprises at least one additional non-nucleic acid spacer moiety.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 28, 29, 30, 31, 32, 33, 34)
- 21. A chimeric immunomodulatory compound (CIC) having a structure selected from the group consisting of
Specification